Atlas Trials

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Clinical trial NCT05231122 · RECRUITING

Trial details

NCT number
NCT05231122
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube Serous AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Start date
2024-03-12
Primary completion
2027-03-15
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.